PROCEPT BioRobotics (PRCT) Stock Price, News & Analysis

Company Overview

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

Key Stats

• Today's Range: $57.90 to $59.06
• 50-Day Range: $48.82 to $62.53
• 52-Week Range: $47.04 to $103.81
• Volume: 916,317 shs
• Average Volume: 818,908 shs
• Market Capitalization: $3.24 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $90.00
• Consensus Rating: Moderate Buy

PROCEPT BioRobotics Stock Analysis - MarketRank™

PROCEPT BioRobotics scored higher than 53% of companies evaluated by MarketBeat, and ranked 472nd out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

PROCEPT BioRobotics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

PROCEPT BioRobotics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for PROCEPT BioRobotics are expected to grow in the coming year, from ($1.75) to ($1.27) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of PROCEPT BioRobotics is -29.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of PROCEPT BioRobotics is -29.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

PROCEPT BioRobotics has a P/B Ratio of 10.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.10% of the float of PROCEPT BioRobotics has been sold short.

Short Interest Ratio / Days to Cover

PROCEPT BioRobotics has a short interest ratio ("days to cover") of 5.6.

Change versus previous month

Short interest in PROCEPT BioRobotics has recently decreased by 4.28%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

PROCEPT BioRobotics does not currently pay a dividend.

Dividend Growth

PROCEPT BioRobotics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

11.10% of the float of PROCEPT BioRobotics has been sold short.

Short Interest Ratio / Days to Cover

PROCEPT BioRobotics has a short interest ratio ("days to cover") of 5.6.

Change versus previous month

Short interest in PROCEPT BioRobotics has recently decreased by 4.28%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 1.28

News Sentiment

PROCEPT BioRobotics has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for PROCEPT BioRobotics this week, compared to 7 articles on an average week.

Search Interest

6 people have searched for PRCT on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added PROCEPT BioRobotics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, PROCEPT BioRobotics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $368,322.00 in company stock.

Percentage Held by Insiders

Only 6.60% of the stock of PROCEPT BioRobotics is held by insiders.

Percentage Held by Institutions

89.46% of the stock of PROCEPT BioRobotics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PRCT Stock Analysis - Frequently Asked Questions

How have PRCT shares performed this year?

PROCEPT BioRobotics' stock was trading at $80.52 at the start of the year. Since then, PRCT stock has decreased by 27.4% and is now trading at $58.4580.
View the best growth stocks for 2025 here.

How were PROCEPT BioRobotics' earnings last quarter?

PROCEPT BioRobotics Co. (NASDAQ:PRCT) issued its quarterly earnings data on Thursday, April, 24th. The company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.04. PROCEPT BioRobotics's revenue was up 55.5% on a year-over-year basis.
Read the conference call transcript.

When did PROCEPT BioRobotics IPO?

PROCEPT BioRobotics (PRCT) raised $126 million in an IPO on Wednesday, September 15th 2021. The company issued 5,500,000 shares at $22.00-$24.00 per share.

Who are PROCEPT BioRobotics' major shareholders?

Top institutional shareholders of PROCEPT BioRobotics include Vanguard Group Inc. (9.27%), Alliancebernstein L.P. (3.87%), T. Rowe Price Investment Management Inc. (2.56%) and Price T Rowe Associates Inc. MD (1.91%). Insiders that own company stock include Frederic H Moll, Reza Zadno, Antal Rohit Desai, Morgan Colby Wood, Kevin Waters, Hisham Shiblaq and Alaleh Nouri.
View institutional ownership trends.

How do I buy shares of PROCEPT BioRobotics?

Shares of PRCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of PROCEPT BioRobotics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that PROCEPT BioRobotics investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), Netflix (NFLX), Tesla (TSLA), NVIDIA (NVDA), SPDR Dow Jones Industrial Average ETF Trust (DIA) and Meta Platforms (META).

Company Calendar

• Last Earnings: 4/24/2025
• Today: 5/27/2025
• Next Earnings (Estimated): 8/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:PRCT
• CIK: 1588978
• Web: www.procept-biorobotics.com
• Phone: 650-232-7200
• Fax: N/A
• Employees: 430
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $90.00
• High Stock Price Target: $112.00
• Low Stock Price Target: $70.00
• Potential Upside/Downside: +54.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.86
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.70)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-105,900,000.00
• Net Margins: -50.07%
• Pretax Margin: -50.07%
• Return on Equity: -38.57%
• Return on Assets: -26.06%

Debt

• Debt-to-Equity Ratio: 0.21
• Current Ratio: 6.02
• Quick Ratio: 5.07

Sales & Book Value

• Annual Sales: $249.12 million
• Price / Sales: 12.98
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.56 per share
• Price / Book: 10.51

Miscellaneous

• Outstanding Shares: 55,329,000
• Free Float: 43,103,000
• Market Cap: $3.23 billion
• Optionable: Optionable
• Beta: 1.10